BioPharmSignal logoBioPharmSignal

Biotech News

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata Therapeutics (LSTA)Lisata TherapeuticsCompany update

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction

Related news

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

ARGXArgenx2026-08-06 11:48 EST

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

GSKGSK plc2026-06-24 12:00 EST

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

ELVNEnliven Therapeutics2026-06-11 12:00 EST

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Lisata Therapeutics

Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.

Recent company news

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

LSTALisata Therapeutics2026-06-10 12:00 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

LSTALisata Therapeutics2026-03-06 23:15 EST

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

LSTALisata Therapeutics2026-01-27 13:00 EST

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTALisata Therapeutics2026-01-21 12:00 EST

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Stock data

Close
1.07 USD
Market cap
31.69M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States